LNAI
HEALTHCARELunai Bioworks Inc
$0.31+0.00 (+0.42%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving LNAI Today?
No stock-specific AI insight has been generated for LNAI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.15$5.50
$0.31
Fundamentals
Market Cap$11M
P/E Ratio—
EPS$-7.56
Dividend Yield—
Dividend / Share—
ROE-3.7%
Profit Margin—
Debt / Equity—
Trading
Volume2.0M
Avg Volume (10D)—
Shares Outstanding36.3M
LNAI News
21 articles- Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s DiseaseYahoo Finance·May 6, 2026
- Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IPYahoo Finance·May 4, 2026
- Stock Market Today: Dow Jones, S&P 500 Futures Edge Lower Amid Extension Of Israel-Lebanon Ceasefire—Intel, SAP, Lunai Bioworks In FocusBenzinga·Apr 24, 2026
- Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma PartnershipsYahoo Finance·Apr 15, 2026
- Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under DiscussionBenzinga·Apr 7, 2026
- BC-Most Active StocksYahoo Finance·Mar 26, 2026
- Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery ApplicationsYahoo Finance·Mar 26, 2026
- Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development ModelYahoo Finance·Mar 19, 2026
- Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease SubtypingYahoo Finance·Feb 19, 2026
- Lunai Bioworks: Fiscal Q2 Earnings SnapshotYahoo Finance·Feb 17, 2026
- Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBCYahoo Finance·Feb 13, 2026
- Lunai Bioworks, Inc. Issues Letter to ShareholdersYahoo Finance·Feb 9, 2026
- Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial DataYahoo Finance·Feb 9, 2026
- Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical WeaponsYahoo Finance·Jan 27, 2026
- Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug DiscoveryYahoo Finance·Jan 26, 2026
- Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks AdvanceYahoo Finance·Dec 18, 2025
- Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B MarketYahoo Finance·Dec 9, 2025
- Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer ModelsYahoo Finance·Nov 25, 2025
- Lunai Bioworks: Fiscal Q1 Earnings SnapshotYahoo Finance·Nov 14, 2025
- Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapyYahoo Finance·Nov 6, 2025
- Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic CompoundsYahoo Finance·Oct 30, 2025
All 21 articles loaded
Price Data
Open$0.31
Previous Close$0.31
Day High$0.33
Day Low$0.30
52 Week High$5.50
52 Week Low$0.15
52-Week Range
$0.15$5.50
$0.31
Fundamentals
Market Cap$11M
P/E Ratio—
EPS$-7.56
Dividend Yield—
Dividend / Share—
ROE-3.7%
Profit Margin—
Debt / Equity—
Trading
Volume2.0M
Avg Volume (10D)—
Shares Outstanding36.3M
About Lunai Bioworks Inc
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. The company is headquartered in Los Angeles, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—